

REMARKS

Prior to examination of the above-captioned application, Applicants respectfully request consideration of this amendment and the remarks made herein. The specification has been amended to include cross-reference to related applications and to insert paragraph numbering. In addition, the specification, at paragraphs [00130] through [00140], has been amended so that the description of the modification of the CryCa1 protein is in accordance with the information provided in Figures 1-5 and SEQ ID NOS:1-12. Applicants assert that these amendments constitute correction of inadvertent typographical errors in the application and hence do not constitute the addition of new matter. Claims 1-36 have been amended to remove multiple dependency from multiply dependent claims and to otherwise conform to U.S. patent practice. Claims 37-40 have been added to capture the full breadth of the subject matter of the specification. Applicants assert that no new matter has been added by the amendments to the claims.

Applicants submit herewith a Sequence Listing in paper and computer-readable form. Please enter this Sequence Listing into the specification of the above-captioned application.

I hereby state that the content of the paper and computer readable copies of the revised Sequence Listing submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same.

I hereby state that the content of the paper and computer readable copies of the revised Sequence Listing, submitted herewith in accordance with 37 C.F.R. § 1.82(f), does not include new matter.

Applicants request an early and favorable consideration of this application.

Respectfully submitted,

BAKER BOTTS L.L.P.

  
Rochelle K. Seide

Bradley B. Geist  
Patent Office Reg. No. 27,551

Rochelle K. Seide  
Patent Office Reg. No. 32,300

Attorneys for Applicants

30 Rockefeller Plaza  
New York NY 10112-4498

(212) 408-2626